Letters
Throughout the year, the AHA comments on a vast number of proposed and interim final rules put forth by the federal regulatory agencies. In addition, AHA communicates with federal legislators to convey the hospital field's position on potential legislative changes that would impact patients and patient care. Below are the most recent letters from the AHA to these bodies.
Latest
Docket No. FDA-2014-D-1525: Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application; Draft Guidance for Industry
Docket No. FDA-2014-D-1524: Repackaging of Certain Human Drug Products by Pharmacies and Outsourcing Facilities: Draft Guidance for Industry
AHA letter to House Energy and Commerce Committee opposing Section 2123, Additional Payment for New Antimicrobial Drugs under Medicare, of the 21st Century Cures Act